/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
With a market cap of $191.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics for a wide range of diseases, including cancer, cardiovascular conditions, and autoimmune disorders. It markets leading medicines such as Enbrel, Prolia, and Repatha while collaborating with partners like AstraZeneca plc and UCB to expand its pipeline and global reach.
The Thousand Oaks, California-based company is expected to release its fiscal Q1 2026 results after the market closes on Thursday, Apr. 30. Ahead of this event, analysts expect AMGN to report an adjusted EPS of $4.75, down 3.1% from $4.90 in the prior year's quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters.